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SUMMARY  13 
Height is a highly heritable, classic polygenic trait with ~700 common associated variants 14 
identified so far through genome-wide association studies. Here, we report 83 height-associated 15 
coding variants with lower minor allele frequencies (range of 0.1-4.8%) and effects of up to 2 16 
cm/allele (e.g. in IHH, STC2, AR and CRISPLD2), >10 times the average effect of common 17 
variants. In functional follow-up studies, rare height-increasing alleles of STC2 (+1-2 cm/allele) 18 
compromised proteolytic inhibition of PAPP-A and increased cleavage of IGFBP-4 in vitro, 19 
resulting in higher bioavailability of insulin-like growth factors. These 83 height-associated 20 
variants overlap genes mutated in monogenic growth disorders and highlight new biological 21 
candidates (e.g. ADAMTS3, IL11RA, NOX4) and pathways (e.g. 22 
proteoglycan/glycosaminoglycan synthesis) involved in growth. Our results demonstrate that 23 
sufficiently large sample sizes can uncover rare and low-frequency variants of moderate to large 24 
effect associated with polygenic human phenotypes, and that these variants implicate relevant 25 
genes and pathways.  26 
 27 
  28 
 3 
INTRODUCTION 29 
Human height is a highly heritable, polygenic trait1,2. The contribution of common DNA 30 
sequence variation to inter-individual differences in adult height has been systematically 31 
evaluated through genome-wide association studies (GWAS). This approach has thus far 32 
identified 697 independent variants located within 423 loci that together explain ~20% of the 33 
heritability of height3. As is typical of complex traits and diseases, most of the height alleles 34 
discovered so far are common (minor allele frequency (MAF) >5%) and are mainly located 35 
outside coding regions, complicating the identification of the relevant genes or functional 36 
variants. Identifying coding variants associated with a complex trait in new or known loci has the 37 
potential to pinpoint causal genes. Furthermore, the extent to which rare (MAF <1%) and low-38 
frequency (1%< MAF ≤ 5%) coding variants also influence complex traits and diseases remains 39 
an open question. Many recent DNA sequencing studies have identified only few such variants4-40 
8, but this limited success could be due to their modest sample size9. Some studies have 41 
suggested that common sequence variants may explain the majority of the heritable variation in 42 
adult height10, making it timely to assess whether and to what extent rare and low-frequency 43 
coding variation contributes to the genetic landscape of this model polygenic trait.  44 
 45 
In this study, we used an ExomeChip11 to test the association between 241,453 variants (83% 46 
coding with MAF ≤5%) and adult height variation in 711,428 individuals (discovery and 47 
validation sample sizes were 458,927 and 252,501, respectively). The ExomeChip is a 48 
genotyping array designed to query in very large sample sizes coding variants identified by 49 
whole-exome DNA sequencing of ~12,000 participants. The main goals of our project were to 50 
determine whether rare and low-frequency coding variants influence the architecture of a model 51 
 4 
complex human trait, such as adult height, and to discover and characterize new genes and 52 
biological pathways implicated in human growth. 53 
  54 
 5 
RESULTS 55 
32 rare and 51 low-frequency coding variants associated with adult height 56 
We conducted single-variant meta-analyses in a discovery sample of 458,927 individuals, of 57 
whom 381,625 were of European ancestry. We validated our association results in an 58 
independent set of 252,501 participants. We first performed standard single-variant association 59 
analyses; technical details of the discovery and validation steps are in Methods (Extended Data 60 
Figs 1-3, Supplementary Tables 1-11). In total, we found 606 independent ExomeChip variants 61 
at array-wide significance (P<2x10-7), including 252 non-synonymous or splice site variants 62 
(Methods and Supplementary Table 11). Focusing on non-synonymous or splice site variants 63 
with MAF <5%, our single-variant analyses identified 32 rare and 51 low-frequency height-64 
associated variants (Extended Data Tables 1-2). To date, these 83 height variants (MAF range 65 
0.1-4.8%) represent the largest set of validated rare and low-frequency coding variants associated 66 
with any complex human trait or disease. Among these 83 variants, there are 81 missense, one 67 
nonsense (in CCND3), and one essential acceptor splice site (in ARMC5) variants.  68 
 69 
We observed a strong inverse relationship between MAF and effect size (Fig. 1). Although 70 
power limits our capacity to find rare variants of small effects, we know that common variants 71 
with effect sizes comparable to the largest seen in our study would have been easily discovered 72 
by prior GWAS, but were not detected. Our results agree with a model based on accumulating 73 
theoretical and empirical evidences that suggest that variants with strong phenotypic effects are 74 
more likely to be deleterious, and therefore rarer12,13. The largest effect sizes were observed for 75 
four rare missense variants, located in the androgen receptor gene AR (rs137852591, 76 
MAF=0.21%, Pcombined=2.7x10
-14), in CRISPLD2 (rs148934412, MAF=0.08%, Pcombined=2.4x10
-77 
20), in IHH (rs142036701, MAF=0.08%, Pcombined=1.9x10
-23), and in STC2 (rs148833559, 78 
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MAF=0.1%, Pcombined=1.2x10
-30). Carriers of the rare STC2 missense variant are ~2.1 cm taller 79 
than non-carriers, whereas carriers of the remaining three variants (or hemizygous men that carry 80 
the X-linked AR-rs137852591 rare allele) are ~2 cm shorter than non-carriers. In comparison, the 81 
mean effect size of common height alleles is ten times smaller in the same dataset. Across all 83 82 
rare and low-frequency non-synonymous variants, the minor alleles were evenly distributed 83 
between height-increasing and -decreasing effects (48% vs. 52%, respectively) (Fig. 1 and 84 
Extended Data Tables 1-2).  85 
 86 
Coding variants in new and known height loci, and heritability explained 87 
Many of the height-associated variants in this ExomeChip effort are located near common 88 
variants previously associated with height. Of the 83 rare and low-frequency non-synonymous 89 
variants, two low-frequency missense variants were previously identified (in CYTL1 and 90 
IL11)3,14 and 47 fell within 1 Mb of a known height signal; the remaining 34 define new loci. We 91 
used conditional analysis in the UK Biobank dataset and confirmed that 38 of these 47 variants 92 
were independent from the previously described height SNPs (Supplementary Table 12). We 93 
validated the UK Biobank conditional results using an orthogonal imputation-based methodology 94 
implemented in the full discovery set (Extended Data Fig. 4 and Supplementary Table 12). In 95 
addition, we found a further 85 common variants and one low-frequency synonymous variant (in 96 
ACHE) that define novel loci (Supplementary Table 12). Thus, our study identified a total of 97 
120 new height loci (Supplementary Table 11).  98 
 99 
We used the UK Biobank dataset to estimate the contribution of the new height variants to 100 
heritability, which is h2~80% for adult height2. In combination, the 83 rare and low-frequency 101 
 7 
variants explained 1.7% of the heritability of height. The newly identified novel common 102 
variants accounted for another 2.4%, and all independent variants, known and novel together 103 
explained 27.4% of heritability. By comparison, the 697 known height SNPs explain 23.3% of 104 
height heritability in the same dataset (vs. 4.1% by the new height variants identified in this 105 
ExomeChip study). We observed a modest positive association between MAF and heritability 106 
explained per variant (P=0.012, Extended Data Fig. 5), with each common variant explaining 107 
slightly more heritability than rare or low-frequency variants (0.036% vs. 0.026%, Extended 108 
Data Fig. 5). 109 
 110 
Gene-based association results 111 
To increase power to find rare or low-frequency coding variants associated with height, we 112 
performed gene-based analyses (Methods and Supplementary Tables 13-15). After accounting 113 
for gene-based signals explained by a single variant driving the association statistics, we 114 
identified ten genes with P<5x10-7 that harbor more than one coding variant independently 115 
associated with height variation (Supplementary Tables 16-17). These gene-based results 116 
remained significant after conditioning on genotypes at nearby common height-associated 117 
variants present on the ExomeChip (Table 1). Using the same gene-based tests in an independent 118 
dataset of 59,804 individuals genotyped on the same exome array, we replicated three genes at 119 
P<0.05 (Table 1). Further evidence for replication in these genes was seen at the level of single 120 
variants (Supplementary Table 18). From the gene-based results, three genes – CSAD, NOX4, 121 
and UGGT2 – fell outside of the loci found by single-variant analyses and are implicated in 122 
human height for the first time.  123 
 124 
Coding variants implicate biological pathways in human skeletal growth  125 
 8 
Prior pathway analyses of height loci identified by GWAS have highlighted gene sets related to 126 
both general biological processes (such as chromatin modification and regulation of embryonic 127 
size) and more skeletal growth-specific pathways (chondrocyte biology, extracellular matrix 128 
(ECM), and skeletal development)3. We used two different methods, DEPICT15 and PASCAL16 129 
(Methods), to perform pathway analyses using the ExomeChip results to test whether coding 130 
variants could either independently confirm the relevance of these previously highlighted 131 
pathways (and further implicate specific genes in these pathways), or identify new pathways. To 132 
compare the pathways emerging from coding and non-coding variation, we applied DEPICT 133 
separately on (1) exome array-wide associated coding variants independent of known GWAS 134 
signals and (2) non-coding GWAS loci, excluding all novel height-associated genes implicated 135 
by coding variants. We identified a total of 496 and 1,623 enriched gene sets, respectively, at a 136 
false discovery rate (FDR) <1% (Supplementary Tables 19-20); similar analyses with PASCAL 137 
yielded 362 and 278 enriched gene sets (Supplementary Tables 21-22). Comparison of the 138 
results revealed a high degree of shared biology for coding and non-coding variants (for 139 
DEPICT, gene set P-values compared between coding and non-coding results had Pearson's r = 140 
0.583, P<2.2x10-16; for PASCAL, Pearson's r=0.605, P<2.2x10-16).  However, some pathways 141 
showed stronger enrichment with either coding or non-coding genetic variation. In general, 142 
coding variants more strongly implicated pathways specific to skeletal growth (such as ECM and 143 
bone growth), while GWAS signals highlighted more global biological processes (such as 144 
transcription factor binding and embryonic size/lethality)(Extended Data Fig. 6). The two 145 
significant gene sets identified by DEPICT and PASCAL that uniquely implicated coding 146 
variants were “BCAN protein protein interaction subnetwork” and “proteoglycan binding.” Both 147 
of these pathways relate to the biology of proteoglycans, which are proteins (such as aggrecan) 148 
 9 
that contain glycosaminoglycans (such as chrondroitin sulfate) and that have well-established 149 
connections to skeletal growth17.  150 
 151 
We also examined which height-associated genes identified by ExomeChip analyses were 152 
driving enrichment of pathways such as proteoglycan binding. Using unsupervised clustering 153 
analysis, we observed that a cluster of 15 height-associated genes is strongly implicated in a 154 
group of correlated pathways that include biology related to proteoglycans/glycosaminoglycans 155 
(Fig. 2 and Extended Data Fig. 7). Seven of these 15 genes overlap a previously curated list of 156 
277 genes annotated in OMIM as causing skeletal growth disorders3; genes in this small cluster 157 
are enriched for OMIM annotations relative to genes outside the cluster (odds ratio=27.6, 158 
Fisher's exact P=1.1x10-5). As such, the remaining genes in this cluster may be strong candidates 159 
for harboring variants that cause Mendelian growth disorders. Within this group are genes that 160 
are largely uncharacterized (SUSD5), have relevant biochemical functions (GLT8D2, a 161 
glycosyltransferase studied mostly in the context of the liver18; LOXL4, a lysyl oxidase expressed 162 
in cartilage19), modulate pathways known to affect skeletal growth (FIBIN, SFRP4)20,21 or lead to 163 
increased body length when knocked out in mice (SFRP4)22.  164 
 165 
Functional characterization of rare STC2 variants 166 
To begin exploring whether the identified rare coding variants affect protein function, we 167 
performed in vitro functional analyses of two rare coding variants in a particularly compelling 168 
and novel candidate gene, STC2. Over-expression of STC2 diminishes growth in mice by 169 
covalent binding and inhibition of the proteinase PAPP-A, which specifically cleaves IGF 170 
binding protein-4 (IGFBP-4), leading to reduced levels of bioactive insulin-like growth factors 171 
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(Fig. 3A)23. Although there was no prior genetic evidence implicating STC2 variation in human 172 
growth, the PAPPA and IGFBP4 genes were both implicated in height GWAS3, and rare 173 
mutations in PAPPA2 cause severe short stature24, emphasizing the likely relevance of this 174 
pathway in humans. The two STC2 height-associated variants are rs148833559 (p.Arg44Leu, 175 
MAF=0.096%, Pdiscovery=5.7x10
-15) and rs146441603 (p.Met86Ile, MAF=0.14%, 176 
Pdiscovery=2.1x10
-5). These rare alleles increase height by 1.9 and 0.9 cm, respectively, suggesting 177 
that they both partially impair STC2 activity. In functional studies, STC2 with these amino acid 178 
substitutions were expressed at similar levels to wild-type, but showed clear, partial defects in 179 
binding to PAPP-A and in inhibition of PAPP-A-mediated cleavage of IGFBP-4 (Fig. 3B-D). 180 
Thus, the genetic analysis successfully identified rare coding alleles that have demonstrable and 181 
predicted functional consequences, strongly confirming the role of these variants and the STC2 182 
gene in human growth.     183 
 184 
Pleiotropic effects  185 
Previous GWAS studies have reported pleiotropic or secondary effects on other phenotypes for 186 
many common variants associated with adult height3,25. Using association results from 17 human 187 
complex phenotypes for which well-powered meta-analysis results were available, we explored 188 
if rare and low-frequency height variants are also pleiotropic. We found one rare and five low-189 
frequency missense variants associated with at least one of the other investigated traits at array-190 
wide significance (P<2x10-7) (Extended Data Fig. 8 and Supplementary Table 23). The minor 191 
alleles at rs77542162 (ABCA6, MAF=1.7%) and rs28929474 (SERPINA1, MAF=1.8%) were 192 
associated with increased height and increased levels of LDL-cholesterol (LDL-C) and total 193 
cholesterol (TC), whereas the minor allele at rs3208856 in CBLC (MAF=3.4%) was associated 194 
with increased height, HDL-cholesterol (HDL-C) and triglyceride (TG), but lower LDL-C and 195 
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TC levels. The minor allele at rs141845046 (ZBTB7B, MAF=2.8%) was associated with both 196 
increased height and body mass index (BMI). The minor alleles at the other two missense 197 
variants associated with shorter stature, rs201226914 in PIEZO1 (MAF=0.2%) and rs35658696 198 
in PAM (MAF=4.8%), were associated with decreased glycated haemoglobin (HbA1c) and 199 
increased type 2 diabetes (T2D) risk, respectively.  200 
  201 
 12 
DISCUSSION 202 
We undertook an association study of nearly 200,000 coding variants in 711,428 individuals, and 203 
identified 32 rare and 51 low-frequency coding variants associated with adult height. 204 
Furthermore, gene-based testing discovered 10 genes that harbor several additional rare/low-205 
frequency variants associated with height, including three genes (CSAD, NOX4, UGGT2) in loci 206 
not previously implicated in height. Given the design of the ExomeChip, which did not consider 207 
variants with MAF <0.004% (or one allele in ~12,000 participants), our gene-based association 208 
results do not rule out the possibility that additional genes with such rarer coding variants also 209 
contribute to height variation; deep DNA sequencing in very large sample sizes will be required 210 
to address this question. In total, our results highlight 89 genes (10 from gene-based testing and 211 
79 from single-variant analyses (four genes have 2 independent coding variants)) that are likely 212 
to modulate human growth, and 24 alleles segregating in the general population that affect height 213 
by more than 1 cm (Extended Data Tables 1-2 and Table 1). The rare and low-frequency 214 
coding variants explain 1.7% of the heritable variation in adult height. When considering all rare, 215 
low-frequency, and common height-associated variants validated in this study, we can now 216 
explain 27.4% of the heritability.  217 
 218 
Our analyses revealed many coding variants in genes mutated in monogenic skeletal growth 219 
disorders, confirming the presence of allelic series (from familial penetrant mutations to mild 220 
effect common variants) in the same genes for related growth phenotypes in humans. We used 221 
gene set enrichment-type analyses to demonstrate the functional connectivity between the genes 222 
that harbor coding height variants, highlighting known as well as novel biological pathways that 223 
regulate height in humans (Fig. 2, Extended Data Fig. 7 and Supplementary Tables 19-22), 224 
and newly implicating genes such as SUSD5, GLT8D2, LOXL4, FIBIN, and SFRP4 that have not 225 
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been previously connected with skeletal growth. Additional interesting height candidate genes 226 
include NOX4, ADAMTS3 and ADAMTS6, PTH1R, and IL11RA (Extended Data Tables 1-2, 227 
Supplementary Tables 17 and 24). NOX4, identified through gene-based testing, encodes 228 
NADPH oxidase 4, an enzyme that produces reactive oxygen species, a biological pathway not 229 
previously implicated in human growth. Nox4-/- mice display higher bone density and reduced 230 
numbers of osteoclasts, a cell type essential for bone repair, maintenance, and remodelling12. We 231 
also found rare coding variants in ADAMTS3 and ADAMTS6, genes that encode 232 
metalloproteinases that belong to the same family than several other human growth syndromic 233 
genes (e.g. ADAMTS2, ADAMTS10, ADAMTSL2). Moreover, we discovered a rare missense 234 
variant in PTH1R that encodes a receptor of the parathyroid hormone (PTH): PTH-PTH1R 235 
signaling is important for bone resorption and mutations in PTH1R cause chondrodysplasia in 236 
humans26. Finally, we replicated the association between a low-frequency missense variant in the 237 
cytokine gene IL11, but also found a new low-frequency missense variant in its receptor gene 238 
IL11RA. The IL11-IL11RA axis has been shown to play an important role in bone formation in 239 
the mouse27,28. Thus, our data confirm the relevance of this signaling cascade in human growth 240 
as well.  241 
 242 
Overall, our findings provide strong evidence that rare and low-frequency coding variants 243 
contribute to the genetic architecture of height, a model complex human trait. This conclusion 244 
has strong implications for the prediction of complex human phenotypes in the context of 245 
precision medicine initiatives. Indeed, although rare, large effect size variants might not explain 246 
most of the heritable disease risk at the population level, they are important to predict the risk to 247 
develop disease for individuals that carry them. Our findings also seem to contrast sharply with 248 
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results from the recent large-scale T2D association study, which found only six variants with 249 
MAF <5% (ref. 29). This apparent difference could simply be explained by the large difference in 250 
sample sizes between the two studies (711,428 for height vs. 127,145 for T2D). When we 251 
consider the fraction of associated variants with MAF<5% among all confirmed variants for 252 
height and T2D, we find that it is similar (9.7% for height vs. 7.1% for T2D). This supports the 253 
strong probability that rarer T2D alleles and more generally, rarer alleles for other polygenic 254 
diseases and traits, will be uncovered as sample sizes continue to increase.   255 
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Figure legends 424 
Figure 1. Variants with a larger effect size on height variation tend to be rarer. We observed an 425 
inverse relationship between the effect size (from the combined “discovery+validation” analysis, 426 
in cm on the y-axis) and the minor allele frequency (MAF) for the height variants (x-axis, from 0 427 
to 50%). We included in this figure the 606 height variants with P<2x10-7. 428 
 429 
Figure 2. Heat map showing subset of DEPICT gene set enrichment results. The full heat map is 430 
available as Extended Data Fig. 7. For any given square, the color indicates how strongly the 431 
corresponding gene (shown on the x-axis) is predicted to belong to the reconstituted gene set (y-432 
axis). This value is based on the gene’s Z-score for gene set inclusion in DEPICT’s reconstituted 433 
gene sets, where red indicates a higher Z-score and blue indicates a lower one. The proteoglycan 434 
binding pathway (bold) was uniquely implicated by coding variants by DEPICT and PASCAL. 435 
To visually reduce redundancy and increase clarity, we chose one representative "meta-gene set" 436 
for each group of highly correlated gene sets based on affinity propagation clustering 437 
(Supplementary Information). Heat map intensity and DEPICT P-values correspond to the 438 
most significantly enriched gene set within the meta-gene set; meta-gene sets are listed with their 439 
database source. Annotations for the genes indicate whether the gene has OMIM annotation as 440 
underlying a disorder of skeletal growth (black and grey) and the minor allele frequency of the 441 
significant ExomeChip (EC) variant (shades of blue; if multiple variants, the lowest-frequency 442 
variant was kept). Annotations for the gene sets indicate if the gene set was also found 443 
significant for EC by PASCAL (yellow and grey) and if the gene set was found significant by 444 
DEPICT for EC only or for both EC and GWAS (purple and green). Abbreviations: GO: Gene 445 
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Ontology; MP: mouse phenotype in the Mouse Genetics Initiative; PPI: protein-protein 446 
interaction in the InWeb database. 447 
 448 
Figure 3. STC2 mutants p.Arg44Leu (R44L) and p.Met86Ile (M86I) show compromised 449 
proteolytic inhibition of PAPP-A. (A) Schematic representation of the role of STC2 in IGF-1 450 
signaling. Partial inactivation of STC2 by height-associated DNA sequence variation could 451 
increase bioactive IGF-1 through reduced inhibition of PAPP-A. (B) Western blot analysis of 452 
recombinant STC2 wild-type and variants R44L and M86I. (C) Covalent complex formation 453 
between PAPP-A and STC2 wild-type or variants R44L and M86I. Separately synthesized 454 
proteins were analyzed by PAPP-A Western blotting following incubation for 8 h. In the absence 455 
of STC2 (Mock lane), PAPP-A appears as a single 400 kDa band (*). Following incubation with 456 
wild-type STC2, the majority of PAPP-A is present as the approximately 500 kDa covalent 457 
PAPP-A:STC2 complex (#), in which PAPP-A is devoid of proteolytic activity towards IGFBP-458 
4. Under similar conditions, incubation with variants R44L or M86I appeared to cause less 459 
covalent complex formation with PAPP-A. The gels are representative of at least three 460 
independent experiments. (D) PAPP-A proteolytic cleavage of IGFBP-4 following incubation 461 
with wild-type STC2 or variants for 1-24 h. Wild-type STC2 causes reduction in PAPP-A 462 
activity, with complete inhibition of activity following 24 h incubation. Both STC2 variants 463 
show increased IGFBP-4 cleavage (i.e. less inhibition) for all time points analyzed. Mean and 464 
standard deviations of three independent experiments are shown. One-way repeated measures 465 
analysis of variance followed by Dunnett’s post-test showed significant differences between 466 
STC2 wild-type and variants R44L (P<0.001) and M86I (P<0.01). 467 
 468 
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Extended Data Figure 1. Flowchart of the GIANT ExomeChip height study design. 469 
 470 
Extended Data Figure 2. Height ExomeChip association results. (A) Quantile-quantile plot of 471 
ExomeChip variants and their association to adult height under an additive genetic model in 472 
individuals of European ancestry. We stratified results based on allele frequency. (B) Manhattan 473 
plot of all ExomeChip variants and their association to adult height under an additive genetic 474 
model in individuals of European ancestry with a focus on the 553 independent SNPs, of which 475 
469 have MAF>5% (grey), 55 have MAF between 1 and 5% (green), and 29 have MAF<1% 476 
(blue). (C) Linkage disequilibrium (LD) score regression analysis for the height association 477 
results in European-ancestry studies. In the plot, each point represents an LD Score quantile, 478 
where the x-axis of the point is the mean LD Score of variants in that quantile and the y-axis is 479 
the mean χ2 statistic of variants in that quantile. The LD Score regression slope of the black line 480 
is calculated based on Equation 1 in Bulik-Sullivan et al.30 which is estimated upwards due to the 481 
small number of common variants (N=15,848) and the design of the ExomeChip. The LD score 482 
regression intercept is 1.4, the λGC is 2.7, the mean χ2 is 7.0, and the ratio statistic of (intercept -1) 483 
/ (mean χ2 -1) is 0.067 (standard error=0.012). (D) Scatter plot comparison of the effect sizes for 484 
all variants that reached significance in the European-ancestry discovery results (N=381,625) and 485 
results including only studies with sample sizes >5000 individuals (N=241,453). 486 
 487 
Extended Data Figure 3. Height ExomeChip association results in African-ancestry 488 
populations. Among the all-ancestry results, we found eight variants for which the genetic 489 
association with height is mostly driven by individuals of African ancestry. The minor allele 490 
frequency of these variants is <1% (or monomorphic) in all ancestries except African-ancestry 491 
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individuals. In individuals of African ancestry, the variants had allele frequencies between 9 and 492 
40%. 493 
 494 
Extended Data Figure 4. Concordance between direct conditional effect sizes using UK 495 
Biobank (x-axis) and conditional analysis performed using a combination of imputation-based 496 
methodology and approximate conditional analysis (SSimp, y-axis). The Pearson’s correlation 497 
coefficient is r=0.85. The dashed line indicates the identity line. The 95% confidence interval is 498 
indicated in both directions. Red, SNPs with Pcond>0.05 in the UK Biobank; Green, SNPs with 499 
Pcond≤0.05 in the UK Biobank. 500 
 501 
Extended Data Figure 5. Heritability estimated for all known height variants in the first release 502 
of the UK Biobank dataset. (A) We observed a weak but significant positive trend between 503 
minor allele frequency (MAF) and heritability explained (P=0.012). (B) Average heritability 504 
explained per variant when stratifying the analyses by allele frequency or genomic annotation. 505 
For heritability estimations in UKBB, variants were pruned to r2 < 0.2 in the 1000 Genomes 506 
Project data set, and the heritability figures are based on h2=80% for height. 507 
 508 
Extended Data Figure 6. Comparison of DEPICT gene set enrichment results based on coding 509 
variation from ExomeChip (EC) or non-coding variation from genome-wide association study 510 
data (GWAS). The x-axis indicates the P-value for enrichment of a given gene set using DEPICT 511 
adapted for EC data, where the input to DEPICT is the genes implicated by coding EC variants 512 
that are independent of known GWAS signals. The y-axis indicates the P-value for gene set 513 
enrichment using DEPICT, using as input the GWAS loci that do not overlap the coding 514 
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signals. Each point represents a meta-gene set, and the best P-value for any gene set within the 515 
meta-gene set is shown. Only significant (false discovery rate < 0.01) gene set enrichment results 516 
are plotted. Colors correspond to whether the meta-gene set was significant for EC only (blue), 517 
GWAS only (green), both but more significant for EC (purple), or both but more significant for 518 
GWAS (orange), and the most significant gene sets within each category are labeled.  A line is 519 
drawn at x = y for ease of comparison. 520 
 521 
Extended Data Figure 7. Heat map showing entire DEPICT gene set enrichment results 522 
(analogous to Fig. 2 in the main text). For any given square, the color indicates how strongly the 523 
corresponding gene (shown on the x-axis) is predicted to belong to the reconstituted gene set (y-524 
axis). This value is based on the gene’s Z-score for gene set inclusion in DEPICT’s reconstituted 525 
gene sets, where red indicates a higher Z-score and blue indicates a lower one.  The proteoglycan 526 
binding pathway was uniquely implicated by coding variants (as opposed to common variants) 527 
by both DEPICT and the Pascal method. To visually reduce redundancy and increase clarity, we 528 
chose one representative "meta-gene set" for each group of highly correlated gene sets based on 529 
affinity propagation clustering (see Methods and Supplementary Information).  Heat map 530 
intensity and DEPICT p-values correspond to the most significantly enriched gene set within the 531 
meta-gene set; meta-gene sets are listed with their database source. Annotations for the genes 532 
indicate whether the gene has OMIM annotation as underlying a disorder of skeletal growth 533 
(black and grey) and the minor allele frequency of the significant EC variant (shades of blue; if 534 
multiple variants, the lowest-frequency variant was kept).  Annotations for the gene sets indicate 535 
if the gene set was also found significant for EC by the Pascal method (yellow and grey) and if 536 
the gene set was found significant by DEPICT for EC only or for both EC and GWAS (purple 537 
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and green). Abbreviations: GO: Gene Ontology; KEGG: Kyoto encyclopedia of genes and 538 
genomes; MP: mouse phenotype in the Mouse Genetics Initiative; PPI: protein-protein 539 
interaction in the InWeb database. 540 
 541 
Extended Data Figure 8. Heatmaps showing associations of the height variants to other 542 
complex traits; –log10(P-values) are oriented with beta effect direction for the alternate allele, 543 
white are missing values, yellow are non-significant (P>0.05), green to blue shading for hits with 544 
positive beta in the other trait and P-values between 0.05 and <2x10-7 and, orange to red shading 545 
for hits with negative beta in the other trait and P-values between 0.05 to <2x10-7. Short and tall 546 
labels are given for the minor alleles. Clustering is done by the complete linkage method with 547 
Euclidean distance measure for the loci. Clusters highlight SNPs that are more significantly 548 
associated with the same set of traits. (A) Variants for which the minor allele is the height-549 
decreasing allele. (B) Variants for which the minor allele is the height-increasing allele. 550 
 551 
Extended Data Table 1. Rare variants associated with adult height. 32 missense or splice site 552 
variants with minor allele frequency <1% in European-ancestry participants that have Pcombined 553 
<2x10-7. The direction of the effect (Beta, standard deviation units) and effect allele frequency 554 
(AF) is given for the alternate (Alt) allele. Genomic coordinates are on build 37 of the human 555 
genome. For each variant, we provide the most severe annotation using the ENSEMBL Variant 556 
Effect Predictor (VEP) tool. N, sample size; Ref, reference allele; SE, standard error. 557 
 558 
Extended Data Table 2. Low-frequency variants associated with adult height. 59 variants (51 559 
missense or nonsense) with minor allele frequency between 1 and 5% in European-ancestry 560 
 30 
participants that have Pcombined <2x10
-7. For TTN-rs16866412 and NOL8-rs921122, the 561 
association is significant (P<2x10-7) upon conditional analysis. The direction of the effect (Beta, 562 
standard deviation units) and effect allele frequency (AF) is given for the alternate (Alt) allele. 563 
For each variant, we provide the most severe annotation using the ENSEMBL Variant Effect 564 
Predictor (VEP) tool. N, sample size; Ref, reference allele; SE, standard error  565 
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METHODS 566 
Study design & participants 567 
The discovery cohort consisted of 147 studies comprising 458,927 adult individuals of the 568 
following ancestries: 1) European descent (N=381,625), 2) African (N=27,494), 3) South Asian 569 
(N=29,591), 4) East Asian (N=8,767); 5) Hispanic (N=10,776) and 6) Saudi (N=695). All 570 
participating institutions and coordinating centers approved this project, and informed consent 571 
was obtained from all subjects. Discovery meta-analysis was carried out in each ancestry group 572 
(except the Saudi) separately as well as in the All group. Validation was undertaken in 573 
individuals of European ancestry only (Supplementary Tables 1-3). Conditional analyses were 574 
undertaken only in the European descent group (106 studies, N=381,625).  575 
 576 
Phenotype 577 
Height (in centimeters) was corrected for age and the genomic principal components (derived 578 
from GWAS data, the variants with MAF >1% on ExomeChip, or ancestry informative markers 579 
available on the ExomeChip), as well as any additional study-specific covariates (e.g. recruiting 580 
center), in a linear regression model. For studies with non-related individuals, residuals were 581 
calculated separately by sex, whereas for family-based studies sex was included as a covariate in 582 
the model. Additionally, residuals for case/control studies were calculated separately. Finally, 583 
residuals were subject to inverse normal transformation. 584 
 585 
Genotype calling  586 
The majority of studies followed a standardized protocol and performed genotype calling using 587 
the designated manufacturer software, which was then followed by zCall31. For 10 studies 588 
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participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology 589 
(CHARGE) Consortium, the raw intensity data for the samples from seven genotyping centers 590 
were assembled into a single project for joint calling11. Study-specific quality control (QC) 591 
measures of the genotyped variants was implemented before association analysis 592 
(Supplementary Tables 1-2).  593 
 594 
Study-level statistical analyses 595 
Individual cohorts were analyzed separately for each ancestry population, with either 596 
RAREMETALWORKER (http://genome.sph.umich.edu/wiki/RAREMETALWORKER) or 597 
RVTEST (http://zhanxw.github.io/rvtests/), to associate inverse normal transformed height data 598 
with genotype data taking potential cryptic relatedness (kinship matrix) into account in a linear 599 
mixed model. These software are designed to perform score-statistics based rare-variant 600 
association analysis, can accommodate both unrelated and related individuals, and provide 601 
single-variant results and variance-covariance matrix. The covariance matrix captures linkage 602 
disequilibrium (LD) relationships between markers within 1 Mb, which is used for gene-level 603 
meta-analyses and conditional analyses32. Single-variant analyses were performed for both 604 
additive and recessive models (for the alternate allele).  605 
 606 
Centralized quality-control 607 
The individual study data were investigated for potential existence of ancestry population 608 
outliers based on 1000 Genome Project phase 1 ancestry reference populations. A centralized QC 609 
procedure implemented in EasyQC33 was applied to individual study association summary 610 
statistics to identify outlying studies: (1) assessment of possible problems in height 611 
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transformation, (2) comparison of allele frequency alignment against 1000 Genomes Project 612 
phase 1 reference data to pinpoint any potential strand issues, and (3) examination of quantile-613 
quantile (QQ) plots per study to identify any problems arising from population stratification, 614 
cryptic relatedness and genotype biases. We excluded variants if they had call rate <95%, Hardy-615 
Weinberg equilibrium P<1x10-7, or large allele frequency deviations from reference populations 616 
(>0.6 for all ancestry analyses and >0.3 for ancestry-specific population analyses). We also 617 
excluded from downstream analyses markers not present on the Illumina ExomeChip array 1.0, 618 
variants on the Y-chromosome or the mitochondrial genome, indels, multiallelic variants, and 619 
problematic variants based on the Blat-based sequence alignment analyses. Meta-analyses were 620 
carried out in parallel by two different analysts at two sites. 621 
 622 
Single-variant meta-analyses 623 
Discovery analyses. We conducted single-variant meta-analyses in a discovery sample of 624 
458,927 individuals of different ancestries using both additive and recessive genetic models 625 
(Extended Data Fig. 1 and Supplementary Tables 1-4). Significance for single-variant 626 
analyses was defined at array-wide level (P<2x10-7, Bonferroni correction for 250,000 variants).  627 
The combined additive analyses identified 1,455 unique variants that reached array-wide 628 
significance (P<2x10-7), including 578 non-synonymous and splice site variants 629 
(Supplementary Tables 5-7). Under the additive model, we observed a high genomic inflation 630 
of the test statistics (e.g. λGC of 2.7 in European-ancestry studies for common markers, Extended 631 
Data Fig. 2 and Supplementary Table 8), although validation results (see below) and additional 632 
sensitivity analyses (see below) suggested that it is consistent with polygenic inheritance as 633 
opposed to population stratification, cryptic relatedness, or technical artifacts (Extended Data 634 
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Fig. 2). The majority of these 1,455 association signals (1,241; 85.3%) were found in the 635 
European-ancestry meta-analysis (85.5% of the discovery sample size) (Extended Data Fig. 2). 636 
Nevertheless, we discovered eight associations within five loci in our all-ancestry analyses that 637 
are driven by African studies (including one missense variant in the growth hormone gene GH1 638 
(rs151263636), Extended Data Fig. 3), three height variants found only in African studies, and 639 
one rare missense marker associated with height in South Asians only (Supplementary Table 640 
7). 641 
 642 
Genomic inflation and confounding. We observed a marked genomic inflation of the test 643 
statistics even after adequate control for population stratification (linear mixed model) arising 644 
mainly from common markers; λGC in European-ancestry was 1.2 and 2.7 for all and common 645 
markers, respectively (Extended Data Fig. 2 and Supplementary Table 8). Such inflation is 646 
expected for a highly polygenic trait like height, and is consistent with our very large sample 647 
size3,34. To confirm this, we applied the recently developed linkage disequilibrium (LD) score 648 
regression method to our height ExomeChip results30, with the caveats that the method was 649 
developed (and tested) with >200,000 common markers available. We restricted our analyses to 650 
15,848 common variants (MAF ≥5%) from the European-ancestry meta-analysis, and matched 651 
them to pre-computed LD scores for the European reference dataset30. The intercept of the 652 
regression of the χ2 statistics from the height meta-analysis on the LD score estimate the inflation 653 
in the mean χ2 due to confounding bias, such as cryptic relatedness or population stratification. 654 
The intercept was 1.4 (standard error = 0.07), which is small when compared to the λGC of 2.7. 655 
Furthermore, we also confirmed that the LD score regression intercept is estimated upward 656 
because of the small number of variants on the ExomeChip and the selection criteria for these 657 
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variants (i.e. known GWAS hits). The ratio statistic of (intercept -1) / (mean χ2 -1) is 0.067 658 
(standard error = 0.012), well within the normal range30, suggesting that most of the inflation 659 
(~93%) observed in the height association statistics is due to polygenic effects (Extended Data 660 
Fig. 2). 661 
 662 
Furthermore, to exclude the possibility that some of the observed associations between height 663 
and rare/low-frequency variants could be due to allele calling problems in the smaller studies, we 664 
performed a sensitivity meta-analysis with primarily Europe-ancestry studies totaling >5,000 665 
participants. We found very concordant effect sizes, suggesting that smaller studies do not bias 666 
our results (Extended Data Fig. 2).  667 
 668 
Conditional analyses. The RAREMETAL R-package35 and the GCTA v1.2436 software were 669 
used to identify independent height association signals across the European descent meta-670 
analysis results. RAREMETAL performs conditional analyses by using covariance matrices in 671 
order to distinguish true signals from those driven by LD at adjacent known variants. First, we 672 
identified the lead variants (P<2x10-7) based on a 1 Mb window centered on the most 673 
significantly associated variant and performed LD pruning (r2<0.3) to avoid downstream 674 
problems in the conditional analyses due to co-linearity. We then conditioned on the LD-pruned 675 
set of lead variants in RAREMETAL and kept new lead signals at P<2x10-7. The process was 676 
repeated until no additional signal emerged below the pre-specified P-value threshold. The use of 677 
a 1Mb window in RAREMETAL can obscure dependence between conditional signals in 678 
adjacent intervals in regions of extended LD. To detect such instances, we performed joint 679 
analyses using GCTA with the ARIC and UK ExomeChip reference panels, both of which 680 
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comprise >10,000 individuals of European descent. With the exception of a handful of variants 681 
in a few genomic regions with extended LD (e.g. the HLA region on chromosome 6), the two 682 
software identified the same independent signals (at P<2x10-7). 683 
 684 
To discover new height variants, we conditioned the height variants found in our ExomeChip 685 
study on the previously published GWAS height variants3 using the first release of the UK 686 
Biobank imputed dataset and regression methodology implemented in BOLT-LMM37. Because 687 
of the difference between the sample size of our discovery set (N=458,927) and the UK Biobank  688 
(first release, N=120,084), we applied a threshold of Pconditional <0.05 to declare a height variant 689 
as independent in this analysis. We also explored an alternative approach based on approximate 690 
conditional analysis36. This latter method (SSimp) relies on summary statistics available from the 691 
same cohort, thus we first imputed summary statistics38 for exome variants, using summary 692 
statistics from the Wood et al. 2014 study3. Conversely, we imputed the top variants from the 693 
Wood et al. 2014 study using the summary statistics from the ExomeChip. Subsequently, we 694 
calculated effect sizes for each exome variant conditioned on the Wood et al. 2014 top variants 695 
in two ways. First, we conditioned the imputed summary statistics of the exome variant on the 696 
summary statistics of the Wood et al. 2014 top variants that fell within 5 Mb of the target 697 
ExomeChip variant. Second, we conditioned the summary statistics of the ExomeChip variant on 698 
the imputed summary statistics of the Wood et al. 2014 hits. We then selected the option that 699 
yielded a higher imputation quality. For poorly tagged variants (?̂?2< 0.8), we simply used up-700 
sampled HapMap summary statistics for the approximate conditional analysis. Pairwise SNP-by-701 
SNP correlations were estimated from the UK10K data (TwinsUK39 and ALSPAC40 studies , 702 
N=3,781). 703 
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 704 
Validation of the single-variant discovery results. Several studies, totaling 252,501 independent 705 
individuals of European ancestry, became available after the completion of the discovery 706 
analyses, and were thus used for validation of our experiment. We validated the single-variant 707 
association results in eight studies, totaling 59,804 participants, genotyped on the Exomechip 708 
using RAREMETAL32. We sought additional evidence for association for the top signals in two 709 
independent studies in the UK (UK Biobank) and Iceland (deCODE), comprising 120,084 and 710 
72,613 individuals, respectively. We used the same QC and analytical methodology as described 711 
above. Genotyping and study descriptives are provided in Supplementary Tables 1-3. For the 712 
combined analysis, we used the inverse-variance weighted fixed effects meta-analysis method 713 
using METAL41. Significant associations were defined as those with a combined meta-analysis 714 
(discovery and validation) Pcombined<2x10
-7. 715 
 716 
We considered 81 variants with suggestive association in the discovery analyses (2x10-717 
7<Pdiscovery≤2x10-6). Of those 81 variants, 55 reached significance after combining discovery and 718 
replication results based on Pcombined<2x10
-7 (Supplementary Table 9). Furthermore, recessive 719 
modeling confirmed seven new independent markers with Pcombined<2x10
-7 (Supplementary 720 
Table 10). One of these recessive signals is due to a rare X-linked variant in the AR gene 721 
(rs137852591, MAF=0.21%). Because of its frequency, we only tested hemizygous men (we did 722 
not identify homozygous women for the minor allele) so we cannot distinguish between a true 723 
recessive mode of inheritance or a sex-specific effect for this variant. To test the independence 724 
and integrate all height markers from the discovery and validation phase, we used conditional 725 
analyses and GCTA “joint” modeling36 in the combined discovery and validation set. This 726 
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resulted in the identification of 606 independent height variants, including 252 non-synonymous 727 
or splice site variants (Supplementary Table 11). If we only consider the initial set of lead 728 
SNPs with P <2x10-7, we identified 561 independent variants. Of these 561 variants (selected 729 
without the validation studies), 560 have concordant direction of effect between the discovery 730 
and validation studies, and 548 variants have a Pvalidation<0.05 (466 variants with Pvalidation 731 
<8.9x10-5, Bonferroni correction for 561 tests), suggesting a very low false discovery rate 732 
(Supplementary Table 11). 733 
 734 
Gene-based association meta-analyses 735 
For the gene-based analyses, we applied two different sets of criteria to select variants, based on 736 
coding variant annotation from five prediction algorithms (PolyPhen2 HumDiv and HumVar, 737 
LRT, MutationTaster and SIFT)42. The mask labeled “broad” included variants with a MAF 738 
<0.05 that are nonsense, stop-loss, splice site, as well as missense variants that are annotated as 739 
damaging by at least one program mentioned above. The mask labeled “strict” included only 740 
variants with MAF <0.05 that are nonsense, stop-loss, splice site, as well as missense variants 741 
annotated as damaging by all five algorithms. We used two tests for gene-based testing, namely 742 
the SKAT43 and VT44 tests. Statistical significance for gene-based tests was set at a Bonferroni-743 
corrected threshold of P<5x10-7 (threshold for 25,000 genes and four tests). The gene-based 744 
discovery results were validated (same test and variants, when possible) in the same eight studies 745 
genotyped on the ExomeChip (N=59,804 participants) that were used for the validation of the 746 
single-variant results (see above, and Supplementary Tables 1-3). Gene-based conditional 747 
analyses were performed in RAREMETAL. 748 
 749 
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Pleiotropy analyses 750 
We accessed ExomeChip data from GIANT (BMI, waist-hip ratio), GLGC (total cholesterol 751 
(TC), triglycerides (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C)), IBPC (systolic 752 
and diastolic blood pressure), MAGIC (glycaemic traits), REPROGEN (age at menarche and 753 
menopause), and DIAGRAM (type 2 diabetes).  For coronary artery disease, we accessed 1000 754 
Genomes Project-imputed GWAS data released by CARDIoGRAMplusC4D45. 755 
 756 
Pathway analyses 757 
DEPICT is a computational framework that uses probabilistically-defined reconstituted gene sets 758 
to perform gene set enrichment and gene prioritization15. For a description about gene set 759 
reconstitution please refer to references 15 and 46. In brief, reconstitution was performed by 760 
extending pre-defined gene sets (such as Gene Ontology terms, canonical pathways, protein-761 
protein interaction subnetworks and rodent phenotypes) with genes co-regulated with genes in 762 
these pre-defined gene set using large-scale microarray-based transcriptomics data. In order to 763 
adapt the gene set enrichment part of DEPICT for ExomeChip data, we made two principal 764 
changes. First and foremost, because DEPICT for GWAS incorporates all genes within a given 765 
LD block around each index SNP, we modified DEPICT to take as input only the gene directly 766 
impacted by the coding SNP. Second, we adapted the way DEPICT adjust for confounders (such 767 
as gene length) by generating null ExomeChip association results using Swedish ExomeChip 768 
data (Malmö Diet and Cancer (MDC), All New Diabetics in Scania (ANDIS), and Scania 769 
Diabetes Registry (SDR) cohorts, N=11,899) and randomly assigning phenotypes from a normal 770 
distribution before conducting association analysis (see Supplementary Information). For the 771 
gene set enrichment analysis of the ExomeChip data, we used significant non-synonymous 772 
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variants statistically independent of known GWAS hits (and that were present in the null 773 
ExomeChip data; see Supplementary Information for details). For gene set enrichment analysis 774 
of the GWAS data, we used all loci (1) with a non-coding index SNP and (2) that did not contain 775 
any of the novel ExomeChip genes. In visualizing the analysis, we used affinity propagation 776 
clustering47 to group the most similar reconstituted gene sets based on their gene memberships 777 
(see Supplementary Information). Within a “meta-gene set”, the best P-value of any member 778 
gene set was used as representative for comparison. DEPICT for ExomeChip was written using 779 
the Python programming language and the code can be found at 780 
https://github.com/RebeccaFine/height-ec-depict. 781 
 782 
We also applied the PASCAL pathway analysis tool16 to association summary statistics for all 783 
coding variants. In brief, the method derives gene-based scores (both SUM and MAX statistics) 784 
and subsequently tests for the over-representation of high gene scores in predefined biological 785 
pathways. We used standard pathway libraries from KEGG, REACTOME and BIOCARTA, and 786 
also added dichotomized (Z-score>3) reconstituted gene sets from DEPICT15. To accurately 787 
estimate SNP-by-SNP correlations even for rare variants, we used the UK10K data (TwinsUK39 788 
and ALSPAC40 studies , N=3781). In order to separate the contribution of regulatory variants 789 
from the coding variants, we also applied PASCAL to association summary statistics of only 790 
regulatory variants (20 kb upstream, gene body excluded) from the Wood et al. study3. In this 791 
way, we could classify pathways driven principally by coding, regulatory or mixed signals. 792 
 793 
STC2 functional experiments 794 
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Mutagenesis, cell culture and transfection. For the generation of STC2 mutants (R44L and 795 
M86I), wild-type STC2 cDNA contained in pcDNA3.1/Myc-His(-) (Invitrogen)23 was used as a 796 
template. Mutagenesis was carried out using Quickchange (Stratagene), and all constructs were 797 
verified by sequence analysis. Recombinant wild-type STC2 and variants were expressed in 798 
human embryonic kidney (HEK) 293T cells (293tsA1609neo, ATCC CRL-3216) maintained in 799 
high-glucose DMEM supplemented 10% fetal bovine serum, 2 mM glutamine, nonessential 800 
amino acids, and gentamicin. The cells are routinely tested for mycoplasma contamination. Cells 801 
(6x106) were plated onto 10 cm-dishes and transfected 18 h later by calcium phosphate 802 
coprecipitation using 10 μg plasmid DNA. Media were harvested 48 h post transfection, cleared 803 
by centrifugation, and stored at -20°C until use. Protein concentrations (58-66 nM) were 804 
determined by TRIFMA using antibodies described previously23. PAPP-A was expressed stably 805 
in HEK293T cells as previously reported48. Expressed levels of PAPP-A (27.5 nM) were 806 
determined by a commercial ELISA (AL-101, Ansh Labs, TX). 807 
 808 
STC2 and PAPP-A complex formation. Culture supernatants containing wild-type STC2 or 809 
variants were adjusted to 58 nM, added an equal volume of culture supernatant containing 810 
PAPP-A corresponding to a 2.1-fold molar excess, and incubated at 37°C. Samples were taken at 811 
1, 2, 4, 6, 8, 16, and 24 h and stored at -20oC. 812 
 813 
Analysis of proteolytic activity. Specific proteolytic cleavage of 125I-labeled IGFBP-4 is 814 
described in detail elsewhere49. Briefly, the PAPP-A:STC2 complex mixtures were diluted 815 
(1:190) to a concentration of 145 pM PAPP-A and mixed with preincubated 125I-IGFBP4 (10 816 
nM) and IGF-1 (100 nM) in 50 mM Tris-HCl, 100 mM NaCl, 1 mM CaCl2. Following 1 h 817 
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incubation at 37oC, reactions were terminated by the addition of SDS-PAGE sample buffer 818 
supplemented with 25 mM EDTA. Substrate and co-migrating cleavage products were separated 819 
by 12% nonreducing SDS-PAGE and visualized by autoradiography using a storage phosphor 820 
screen (GE Healthcare) and a Typhoon imaging system (GE Healthcare). Band intensities were 821 
quantified using ImageQuant TL 8.1 software (GE Healthcare). 822 
 823 
Western blotting. STC2 and covalent complexes between STC2 and PAPP-A were blotted onto 824 
PVDF membranes (Millipore) following separation by 3-8% SDS-PAGE. The membranes were 825 
blocked with 2% Tween-20, and equilibrated in 50 mM Tris-HCl, 500 mM NaCl, 0.1% Tween-826 
20, pH 9 (TST). For STC2, the membranes were incubated with goat polyclonal anti-STC2 827 
(R&D systems, AF2830) at 0.5 μg/ml in TST supplemented with 2% skim milk for 1 h at 20°C. 828 
For PAPP-A:STC2 complexes, the membranes were incubated with rabbit polyclonal anti-829 
PAPP-A50 at 0.63 μg/ml in TST supplemented with 2% skim milk for 16 h at 20°C. Membranes 830 
were washed with TST and subsequently incubated with polyclonal swine anti-rabbit IgG-HRP 831 
(DAKO, P0217) or polyclonal rabbit anti-goat IgG-HRP (DAKO, P0449), respectively, diluted 832 
1:2000 in TST supplemented with 2% skim milk for 1 h at 20°C. Following washing with TST, 833 
membranes were developed using enhanced chemiluminescence (ECL Prime, GE Healthcare). 834 
Images were captured using an ImageQuant LAS 4000 instrument (GE Healthcare). 835 
 836 
  837 
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Table 1. Ten height genes implicated by gene-based testing. These genes meet our three criteria for statistical significance: (1) gene-based P<5x10-7, 
(2) the gene does not include variants with P<2x10-7, and (3) the gene-based P-value is at least two orders of magnitude smaller than the P-value for 
the most significant variant within the gene. For each gene, we provide P-values for the four different gene-based tests applied. P-values in bold are 
the most significant results for a given gene. 1Validation (N=59,804) and combined results using the same test and (when possible) variants. 2When 
the gene is located in a locus identified by our single-variant analysis (1 Mb window), we conditioned the gene-based association result on genotypes 
at the single variant(s). 3If the gene falls within a known GWAS height locus, we mention if it was predicted to be causal using bioinformatic tools 
(ref. 3). NA, not applicable. 
Gene 
Discovery gene-based P-value 
Validation 
P-value1 
Combined 
P-value1 
Conditional 
P-value2 
Note3 SKAT-
broad 
VT-
broad 
SKAT-
strict 
VT-
strict 
OSGIN1 4.3x10-11 4.5x10-5 0.19 0.18 0.048 2.6x10-12 7.7x10-11 Known locus. No predicted causal genes. 
CRISPLD1 2.2x10-7 6.7x10-11 8.5x10-6 8.9x10-7 0.50 1.2x10-12 NA 
Known locus, sentinel GWAS SNP not tested 
on ExomeChip. CRISPLD1 was predicted to be 
causal. 
CSAD 2.3x10-8 2.4x10-9 0.83 0.59 0.54 2.0x10-9 NA New locus. 
SNED1 1.9x10-5 4.3x10-9 NA NA 0.083 4.5x10-10 1.4x10-9 
Known locus. SNED1 was not predicted to be 
causal. 
G6PC 1.3x10-5 3.6x10-8 5.5x10-6 1.3x10-6 0.24 5.2x10-8 3.9x10-8 
Known locus, G6PC was not predicted to be 
causal. G6PC is mutated in glycogen storage 
disease Ia. 
NOX4 5.1x10-6 1.4x10-7 NA NA 0.013 5.5x10-9 NA New locus. 
UGGT2 3.0x10-5 2.6x10-7 2.3x10-5 4.8x10-7 0.64 3.4x10-7 NA New locus. 
FLNB 2.2x10-6 5.1x10-4 2.4x10-9 3.2x10-6 0.016 8.6x10-11 3.6x10-9 
Known locus. FLNB was predicted to be causal. 
FLNB is mutated in atelosteogenesis type I. 
B4GALNT3 2.4x10-5 1.9x10-5 1.8x10-5 3.1x10-7 0.79 4.3x10-7 7.7x10-7 
Known locus. B4GALNT3 was predicted to be 
causal. 
CCDC3 6.3x10-4 6.3x10-6 3.0x10-7 5.4x10-9 0.080 1.2x10-9 1.6x10-9 
Known locus. CCDC3 was predicted to be 
causal. 
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endochondral bone morphogenesis (GO, 2.826 x 10−17)
regulation of chondrocyte differentiation (GO, 1.73 x 10−14)
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regulation of osteoblast differentiation (GO, 1.662 x10−13)
platelet−derived growth factor binding (GO, 2.16 x 10−5)
abnormal cutaneous collagen fibril morphology (MP, 6.06 x 10−9)
extracellular matrix (GO, 4.631 x 10−8)
proteoglycan binding (GO, 6.587 x 10−5)
basement membrane (GO, 3.02 x 10−5)
TGFB2 PPI subnetwork (PPI, 7.819 x 10−10)
glycosaminoglycan binding (GO, 1.042 x10−6)
GDAP1L1 PPI subnetwork (PPI, 1.823 x 10−5)
chondroitin sulfate proteoglycan metabolic process (GO, 5.279 x 10−9)
heparan sulfate proteoglycan biosynthetic process (GO, 1.285 x 10−5)
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